CD34⁺ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina.

ABSTRACT: Patients with refractory angina who are suboptimal candidates for further revascularization have improved exercise time, decreased angina frequency, and reduced major adverse cardiac events with intramyocardial delivery of CD34⁺ cells. However, the effect of CD34⁺ cell therapy on health care expenditures before and after treatment is unknown. We determined the effect of CD34⁺ cell therapy on cardiac-related hospital visits and costs during the 12 months following stem cell injection compared with the 12 months prior to injection. Cardiac-related hospital admissions and procedures were retrospectively tabulated for patients enrolled at one site in one of three double-blinded, placebo-controlled CD34⁺ trials in the 12 months before and after intram

SUBMITTER: Johnson GL 

PROVIDER: S-EPMC7519768 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature